v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Current assets:    
Cash $ 8,088 $ 23,014
Accounts receivable - trade 175 484
Accounts receivable - unbilled 0 122
Work in process 26 22
Prepaid expenses and other current assets 283 264
Total Current Assets 8,572 23,906
Fixed assets, net of accumulated depreciation 25,589 25,574
Intangible assets, net of accumulated amortization 1,823 2,092
Security deposit 26 28
Total Assets 36,010 51,600
Current liabilities:    
Accounts payable (related party of $87 and $200 as of June 30, 2017 and 2016, respectively) 749 1,177
Accrued expenses (related party of $650 and $623 as of June 30, 2017 and 2016, respectively) 924 920
Capital lease obligation - current portion 183 170
Deferred revenue 157 24
Total Current Liabilities 2,013 2,291
Capital lease obligation - net of current portion 25,082 25,265
Total Liabilities 27,095 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - no par value; 1,000,000 shares authorized; 1 and 0 shares issued and outstanding as of June 30, 2017 and 2016, respectively 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,118,510 and 89,109,410 shares issued and outstanding as of June 30, 2017 and 2016, respectively 89 89
Additional paid-in capital 80,977 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (72,123) (57,591)
Total iBio, Inc. Stockholders’ Equity 8,914 9,937
Noncontrolling interest 1 14,107
Total Equity 8,915 24,044
Total Liabilities and Equity $ 36,010 $ 51,600

Source

v3.7.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Revenues $ 394 $ 948
Operating expenses:    
Research and development (related party of $957 and $1,036), net of grant income of $131 and $65 4,117 3,156
General and administrative (related party of $775 and $565) 10,551 7,685
Total operating expenses 14,668 10,841
Operating loss (14,274) (9,893)
Other income (expense):    
Interest expense (related party of $1,928 and $807) (1,929) (807)
Interest income 39 22
Royalty income 25 21
Total other income (expense) (1,865) (764)
Consolidated net loss (16,139) (10,657)
Net loss attributable to noncontrolling interest 1,607 893
Net loss attributable to iBio, Inc. (14,532) (9,764)
Preferred stock dividends (90) 0
Net loss available to iBio, Inc. (14,622) (9,764)
Comprehensive loss:    
Consolidated net loss (16,139) (10,657)
Other comprehensive loss - foreign currency translation adjustments 0 (4)
Comprehensive loss $ (16,139) $ (10,661)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.16) $ (0.12)
Weighted-average common shares outstanding - basic and diluted 89,112 80,973

Source

v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities:    
Net loss $ (16,139) $ (10,657)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 1,010 1,245
Amortization of intangible assets 350 363
Depreciation 1,326 577
Loss on abandonment of intangible assets 0 33
Changes in operating assets and liabilities    
Accounts receivable - trade 309 (39)
Accounts receivable - unbilled 122 (122)
Work in process (4) (22)
Prepaid expenses and other current assets (19) (82)
Security deposit 2 (28)
Accounts payable (257) (125)
Accrued expenses 4 761
Deferred revenue 133 24
Net cash used in operating activities (13,163) (8,072)
Cash flows from investing activities:    
Additions to intangible assets (270) 0
Purchases of fixed assets (1,323) (68)
Net cash used in investing activities (1,593) (68)
Cash flows from financing activities:    
Proceeds from sale of common stock 0 6,220
Proceeds from exercise of warrants 0 1,009
Capital contribution - noncontrolling interest 0 15,000
Payment of capital lease obligation (170) (565)
Net cash (used in) provided by financing activities (170) 21,664
Effect of exchange rate changes 0 (4)
Net increase (decrease) in cash (14,926) 13,520
Cash - beginning of year 23,014 9,494
Cash - end of year 8,088 23,014
Schedule of non-cash activities:    
Issuance of preferred stock for acquisition of additional interest in subsidiary 12,499 0
Unpaid intangible assets included in accounts payable 7 129
Fixed assets included in accounts payable in FY 2016, paid in FY 2017 (71) 0
Unpaid fixed assets included in accounts payable 87 71
Purchase of fixed assets financed by capital lease 0 26,000
Supplemental cash flow information:    
Cash paid during the year for interest $ 1,930 $ 485

Source